Zusammenfassung
Klinische Bedeutung des Prolaktins und seiner Sekretionsstörungen. In der gynäkologischen Sprechstunde wird die Hyperprolaktinämie im Zusammenhang mit Zyklusstörungen als eine der häufigsten endokrinen Störungen diagnostiziert. Prolaktin nimmt eine zentrale Bedeutung in der Reproduktionsendokrinologie ein. Eine gestörte Prolaktinsekretion kann außer mit einer Funktionsstörung des Ovars auch mit Funktionsstörungen anderer endokriner Organe wie der Schilddrüse und der Nebennierenrinde verbunden sein. Auf der anderen Seite ist eine gestörte Prolaktinsekretion u. U. selbst Symptom und Begleiterscheinung anderer Endokrinopathien, Stoffwechselstörungen oder Allgemeinerkrankungen (s. nachfolgende übersicht). Daher stellt die Bestimmung des Prolaktinspiegels im Blut eine der zentralen differenzialdiagnostischen Maßnahmen in der Abklärung von Hormon- und Fertilitätsstörungen dar.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Alvarez C, Alonso-Muriel I, Garcfa G et al. (2007) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22: 3210–3214
Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C (2003) Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 149: 17–22
Archer DF, Josimovich JB (1975) Response of serum prolactin to exogenous stimulation. Fertil Steril 26: 627
Asa SL, Penz G, Kovacs K, Ezrin C (1982) Prolactin cells in the human pituitary. Arch Pathol Lab Med 106: 360
Bals-Pratsch M, De Geyter C, Müller T et al. (1997) Episodic variations of prolactin, TSH, LH, melatonin and cortisol and relationship to sleep stages in infertile women with subclinical hypothyroidism. Hum Reprod 12: 896–904
Bals-Pratsch M, Schober O, Hanker JP, de Geyter C, Schneider HPG (1993) Schilddrüsenfunktionsstörungen und Sterilität der Frau. Zentralbl Gynäkol 115: 118–223
Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ (2005) Pituitary imaging is indicated for the evaluation of hyperprolactinemia Fertil Steril 84: 181–185
Ben-David M, Schenker JG (1983) Transient hyper-prolactinemia: a correctable cause of idiopathic female infertility. J Clin Endocrinol Metab 57: 442
Bohnet HG (1981) Prolaktin und seine Bedeutung für die Frau. Grosse, Berlin
Bohnet HG (1986) Hyperprolaktinämie. Grosse, Berlin
Bohnet HG, Dahlen HG, Wuttke W, Schneider HPG (1976) Hyperprolactinemic anovulatory syndrome. J Clin Endocrinol Metab 42: 132
Bohnet HG, Fiedler K, Leidenberger FA (1981) Subclinical hypothyreoidism and infertility. Lancet II: 1278
Bohnet HG, Kato K, Niemann D (1986) Thyroid function and prolactin secretion in women with menstrual disorders and/or infertility. In: Medeiros-Neto G, Gaitan E (eds) Frontiers in thyroidology I. Plenum, New York, p 270
Bonhoff A, Vuille JC, Gomez F, Gellersen B (1995) Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. Exp Clin Endocrinol 103: 252
Brue T, Pellegrini I, Priou A et al. (1992) Prolactinomas and resistance to dopamine agonists. Horm Res 38: 84
Buckman MR, Peake GT, Srivastava L (1981) Patterns of spontaneous LH release in normo-and hyper-prolactinaemic women. Acta Endocrinologica 97: 305
Colao A, Abs R, Bärcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.Clin Endocrinol (Oxf) 68: 66–71
Cowie AT, Tindal JS (1971) The physiology of lactation. In: Dawson H, Greenfield ADM, Whittam R, Brindley GS (eds) Monographs of the physiological society, 22. Edward Arnold Ltd., London, p 105
Crosignani PG (2006) Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 125: 152–164
Denef C, Andries M (1983) Evidence for paracrine interaction between gonadotrophs and lactotrophs in pituitary cell aggregates. Endocrinol 112: 813
Divers WA, Yen SSC (1983) Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 62: 425
Evans WS, Thorner MO (1984) Mechanisms for hypogonadism in hyperprolactinaemia. Sem Reprod Endocrinol 2: 9
Fahlbusch R, Nistor R, Buchfelder M, Huk W (1988) Imaging magnetic resonance (MEI) in the preoperative diagnosis of pituitary adenomas: a comparison with CT. In: Landolt AM et al. (eds) Advances in pituitary adenoma research. Pergamon, Oxford, p 117
Falk RJ (1992) Isolated prolactin deficiency: a case report. Fertil Steril 58: 1060
Fink U, Bauer WM, Hartmann N et al. (1988) Efficiency of MRI in patients with pituitary adenomas. In: Landolt AM et al. (eds) Advances in pituitary adenoma research. Pergamon, Oxford, p 1
Fish LH, Mariash CN (1988) Hyperprolactinemia, infertility and hypothyroidism. Arch Intern Med 148: 709–711
Franks S, Murray AF, Jequier AM et al. (1975) Incidence and significance of hyperprolactinaemia in women with amenorrhoea. Clin Endocrinol 4: 597
Gellersen B, DiMattia GE, Friesen HG, Bohnet HG (1989) Prolactin (PRL) mRNA from human decidua differs from pituitary PRL mRNA but resembles the IM-9-P3 lymphoblast PRL transcript. Mol Cell Endocrinol 64: 127
Ginsburg J, Hardiman P, Thomas M (1991) Vaginal bromocriptine. Letter. Lancet 338ii: 1205–1206
Glasow A, Breidert M, Haidan A et al. (1996) Functional aspects of the effects of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab 81: 3103
Gomez F, Reyes FI, Faiman C (1977) Nonpuerperal galactorrhea and hyperprolactinemia. Am J Med 62: 648
Grossman A (1987) Opioid peptides and reproductive function. Sem Reprod Endocrinol 5: 115
Hamon-Kérautret M, Leclerc X, Dewailly D, Pruvo JP, Fossati P, Clarisse J (1994) Pituitary microadenomas: experience with Gd-DOTA-enhanced MR imaging at 0.5 Telsa. Eur J Radiol 18: 185–190
Ivân G, Szigeti-Csúcs N, Olâh M, Nagy GM, Gáth MI (2005) Treatment of pituitary tumors: dopamine agonists. Endocrine 28: 101–110
Jackson RD, Wortsman J, Malarkey WB (1985) Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 61: 258
Jara LJ, Cruz-Cruz P, Saavedra MA et al. (2007) Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann N Y Acad Sci 1110: 297–304
Johnston JM, Amico JA (1986) A prospective longitudinal study of the release of oxytocin and prolactin in response to infant suckling in long term lactation. J Clin Endocrinol Metab 62: 653–657
Jürgensen O, Bardee B (1982) Zur Psychodynamik der Hyperprolaktinämie. Gynäkologe 15: 190
Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363–367
Kleinberg DL (1984) Medical treatment of pituitary tumors. Sem Reprod Endocrinol 2: 63
Kletzky OA (1984) Diagnostic approaches to hyperprolactinemic states. Sem Reprod Endocrinol 2: 23
Klibanski A (1984) Osteoporosis and hyperprolactniemia. Sem Reprod Endocrinol 2: 93
Klibanski A, Neer RM, Beitins IZ et al. (1980) Decreased bone density in hyper-prolactinemic women. N Engl J Med 303: 1511
Koppelman MCS, Kurtz DW, Morrish KA et al. (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59: 1050
Kreft B, Peters A, Kerner W (1996) The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation. Dtsch Med Wochenschr 121: 865–868
Lappöhn RE, van de Wiel HBM, Brownell J (1992) The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril 58: 321
Larrea F, Sandoval JL, Salinas E et al. (1995) Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia. Clin Endocrinol 43: 591
Lengyel AMJ, Mussio W, Imamura P et al. (1993) Long-acting injectable bromocriptin (Parlodel LAR) in the chronic treatment of prolactinsecreting macroadenomas. Fertil Steril 59: 980
Leyendecker G, Nocke W, Schmidt-Gollwitzer M et al. (1977) Klinik der hyperprolaktinämischen Amenorrhoe. Gynäkologe 10: 93
Lobo RA, Kletzky OA, Kaptein EM, Goebelsmann U (1980) Prolactin modulation of dehydroepiandrosterone sulfate secretion. Am J Obstet Gynecol 138: 632
Loucopoulos A, Jewelewicz R (1984) Prolactinomas and pregnancy. Sem Reprod Endocrinol 2: 83
Lüdecke DK, Herrmann HD, Hörmann C, Desaga U, Saeger W (1983) Microsurgery and combination with dopamine agonists in the treatment of prolactinomas. In: Tolis G et al. (eds) Prolactin and prolactinomas. Raven, New York, p 453
Marchetti B, Labrie F (1982) Prolactin inhibits pituitary luteinizing hormone-releasing hormone receptors in the rat. Endocrinology 111: 1209
Marcovitz S, Hardy J (1984) Combined medical and surgical treatment of prolactin-producing pituitary tumors. Sem Reprod Endocrinology 2: 73
McNatty JP, Sawers RS, McNeilly AS (1974) A possible role for prolactin in control of steroid secretion by the human Graafian follicle. Nature 250: 653
Meema S, Bunker ML, Meema HE (1975) Preventive effect of estrogen on postmenopausal bone loss: a follow-up study. Arch Intern Med 135: 1436
Melmed S (1984) Control of prolactin synthesis and secretion. Sem Reprod Endocrinol 2: 1
Missale C, Losa M, Sigala S et al. (1996) Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol 10: 272
Molitch ME (1985) Pregnancy and the hyperprolactinemic women. N Engl J Med 312: 1364
Moltz L, Trapp M, Bispink G, Leidenberger F (1987) Rationelle hormonale Diagnostik der sekundären Amenorrhö. Geburtshilfe Frauenheilkd 47: 228
Moult PJA, Rees LH, Besser GM (1982) Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea and the response to bromocriptine therapy. Clin Endocrinol 16: 153
Nikolics K, Mason AJ, Szonyi E et al. (1985) A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 116: 511
Parker LN, Chang S, Odell WD (1978) Adrenal androgens in patients with chronic marked elevation of prolactin. Clin Endocrinol 8: 1
Pearce JM, McGarrick G, Chamberlain GVP, Jeffcoate SL (1980) Lack of effect of interview and gynaecological examination on plasma levels of prolactin and cortisol. Br J Obstet Gynaecol 87: 366
Peters F, Schuth W, Breckwoldt M (1982) Ist die Palpation der Mamma ein Störfaktor für die Prolaktinbestimmung? Geburtshilfe Frauenheilkd 42: 223
Priou A, Bruder N, Bégou D et al. (1995) Glycosylated and non-glycosylated prolactin forms are increased after opioid administrations as part of surgical anaesthesia. Clin Endocrinol 43: 213
Quigley ME, Sheehan KL, Casper RF, Yen SSC (1980) Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma. J Clin Endocrinol Metab 50: 427
Rjosk HK, Fahlbusch R, von Werder K (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol (Copenh) 100: 337–346
Rjosk HK, von Werder K, Fahlbusch R (1976) Hyperprolaktinämische Amenorrhoe. Geburtshilfe Frauenheilkd 36: 575
Rossmanith WG (1994) Neuroendokrine Steuerung menschlicher Reproduktion. Ullstein Mosby, Wiesbaden, S. 15
Rossmanith WG, Boscher S, Ulrich U, Benz R (1993) Chronobiology of prolactin secretion in women: diurnal and sleep-related variations in the pituitary lactotroph sensitivity. Neuroendocrinology 58: 263
Rossmanith WG, Hohl B, Lüttke B (1995) Thyrotropin (TSH) and prolactin (PRL) secretion in lactating and non-lactating women. Gynecol Endocrinol 9: 181
Rossmanith WG, Scherbaum WA (1994) Die Schilddrüse und ihre Bedeutung für die weibliche Reproduktion. Dtsch ärztebl 91: A5362
Rossmanith WG, Yen SSC, Rasmussen DD (1989) Synchronous pulsatile release of luteinzing hormone and immunoreactive beta-endorphin from the human pituitary in vitro. J Neuroendocrinology 2: 91
Ruiz-Velasco V (1984) Pregnancy in hyperprolactinemia. Fertil Steril 41: 793
Schneider HPG, Bohnet HG (1977) Hyperprolaktinämische Amenorrhoe und Anovulation. Gynäkologe 10: 84
Schneider HPG, Hanker JP (1988) Zyklusstörung und Diagnostik der funktionell gestörten Fertilität. In: Schneider HPG, Lauritzen C, Nieschlag E (Hrsg.) Grundlagen und Klinik der menschlichen Fortpflanzung. De Gruyter, Berlin, S 449
Seppälä M, Hirvonen E (1975) Raised serum prolactin levels associated with hirsutism and amenorrhoea. Br Med J 4: 144
Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocrine Rev 16: 354
Sluijmer AV, Lappöhn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58: 72
Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ (2002) Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 87: 5410–5415
Soule SG, Jacobs HS (1995) Prolactinomas: present day management. Br J Obstet Gynecol 102: 178
Spark RF, Baker R, Bienfang DC, Bergland R (1982) Reduktion von Hypophysentumoren durch Bromocriptin. Requiem für chirurgische Eingriffe an der Hypophyse? JAMA (Dtsch Ausgabe) 1: 483
Speroff L, Glass RH, Kase NG (1994) Clinical gynecologic endocrinology and infertility. Lippincott, Williams & Wilkins, Philadelphia, p 73
Tyson JE, Zacur HA, Huth J, Chapanis N (1992) Hyperprolactinemia blunts awareness of distress and depression: evidence for a specific behavioral and environmental setting for galactorrhea-amenorrhea. Sem Reprod Endocrinol 10: 246
Vermeulen A, Suy E, Rubens R (1977) Effect of prolactin on plasma DHEA (s) levels. J Clin Endocrinol Metab 44: 1222
von Werder K (1991) Therapie von Mikro-und Makroprolaktinomen. Dtsch Med Wschr 116: 25–27
von Werder K, Eversmann T, Rjosk HK, Fahlbusch R (1982) Treatment of hyperprolactinemia. In: Ganong WF, Martini L (eds) Frontiers in neuroendocrinology. Raven, New York, p 123
Waters MJ, Lusins S, Friesen HG (1984) Immunological and physiochemical evidence for tissue specific prolactin receptors in the rabbit. Endocrinology 114: 1
Weise HC, Moltz L, Bispink G, Leidenberger F (1989) Rationelle hormonale Diagnostik der Oligomenorrhö. Geburtshilfe Frauenheilkd 49: 694
Wenzel KW (1981) Pharmacological interference with in vitro tests of thyroid function. Metabolism 30: 717
Wunder DM, Bersinger NA, Yared M, Kretschmer R, Birkhäuser MH (2008) Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 89: 927–933
Yazigi RA, Quintero CH, Salameh WA (1997) Prolactin disorders. Fertil Steril 67: 215–225
Yen SSC (1996) Prolactin in human reproduction. In: Yen SSC, Jaffe RB (eds) Reproductive endocrinology. Saunders, Philadelphia, p 237
Yuen BH (1978) Bromocriptine, pituitary tumours, and pregnancy. Lancet 2: 14
Yuen BH (1992) Etiology and treatment of hyperprolactinemia. Sem Reprod Endocrinol 10: 228
Zacur HA, Foster GV (1992) Hyperprolactinemia and polycystic ovarian syndrome. Sem Reprod Endocrinol 10: 236
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Bals-Pratsch, M. (2009). Störungen des Prolaktinhaushalts. In: Leidenberger, F., Strowitzki, T., Ortmann, O. (eds) Klinische Endokrinologie für Frauenärzte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89760-6_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-89760-6_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-89759-0
Online ISBN: 978-3-540-89760-6
eBook Packages: Medicine (German Language)